TY - JOUR T1 - Molecular Action of ADAMTS13 and Transfusion Therapies of Thrombotic Thrombocytopenia Pupura JF - American Society for Clinical Laboratory Science JO - Clin Lab Sci DO - 10.29074/ascls.120.002287 SP - ascls.120.002287 AU - Billie Ketelsen Y1 - 2020/01/01 UR - http://hwmaint.clsjournal.ascls.org/content/early/2020/07/31/ascls.120.002287.abstract N2 - Thrombotic Thrombocytopenia Pupura (TTP) is a disease that is classified by abnormal functioning of the ADAMTS13 protease. ADAMTS13 protease impairment can be caused by genetic mutations at the gene level or through autoantibodies that are formed within the circulation. Congenital mutations account for about 5-10% of the TTP population while the acquired version is more common. The acquired version of TTP is due to inhibitory and non-inhibitory autoantibodies that affect the ADAMTS13 protease. Both congenital and acquired TTP are treated through transfusion therapy with therapeutic plasma exchange (TPE). TPE is used to remove the autoantibodies and any mutated ADAMTS13 proteases in the circulation while providing the addition of normal functioning ADAMTS13 to the circulation. ER -